Skip to main content
. 2020 Apr 27;12(4):149–158. doi: 10.4240/wjgs.v12.i4.149

Table 3.

Survival analysis

Univariate
Multivariate
P value OR (95%CI) P value OR (95%CI)
Date of recurrence 0.006 1.00 (1.00-1.00) 0.79
Age at recurrence (years) 0.93
Time from transplant < 0.001 0.977 (0.966-0.988) 0.001 0.977 (0.963-0.991)
Number of tumours < 0.001 1.01 (1.01-1.02) 0.33
Size of largest tumour 0.02 1.11 (1.02-1.20) 0.02 1.13 (1.02-1.24)
Number of organs involved 0.01 1.14 (1.11-1.89) 0.27
Site of recurrence
Liver 0.01 1.62 (1.13-2.31) 0.01 1.92 (1.14-3.25)
Lung 0.43
Bone 0.17
Peritoneal 0.46
Adrenal 0.52
Lymph node 0.49
AFP upon recurrence 0.02 1.00 (1.00-1.00) 0.02 1.00 (1.00-1.00)
Immunosuppression after recurrence
mTOR inhibitor < 0.001 0.485 (0.339-0.695) 0.04 0.482 (0.241-0.966)
Calcineurin Inhibitor 0.07
Tacrolimus trough (μg/L) 0.002 1.13 (1.04-1.22) 0.16
Treatment
Surgery < 0.001 0.380 (0.240-0.601) 0.22
RFA 0.16
TACE 0.32
Radiotherapy 0.90
Targeted therapy 0.97
Immunotherapy 0.80
Supportive < 0.001 2.34 (1.49-3.67) 0.73

AFP: Alpha-fetoprotein; RFA: Radiofrequency ablation; TACE: Trans-arterial chemoembolization; mTOR: Mammalian target of rapamycin.